Literature DB >> 19196932

Neuropsychological deficits in Huntington's disease gene carriers and correlates of early "conversion".

Jason Brandt1, Anjeli B Inscore, Julianna Ward, Barnett Shpritz, Adam Rosenblatt, Russell L Margolis, Christopher A Ross.   

Abstract

The authors examined whether the baseline cognitive functioning of 21 clinically normal huntingtin mutation carriers who developed manifest Huntington's disease on follow-up differed from that of 49 mutation carriers who remain asymptomatic over the same period in a longitudinal study. One hundred thirty-four gene-negative offspring of Huntington's disease patients were studied as well. Overall, there were no differences in cognitive test performance among the three groups. However, "converters" who developed signs of Huntington's disease within 8.6 years demonstrated poorer performance on the Wisconsin Card Sorting Test at baseline. People with the Huntington's disease mutation who are carefully examined neurologically and found to be asymptomatic have, at most, very minimal problem-solving impairment, and only if they are within a few years of clinical onset.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19196932      PMCID: PMC2966303          DOI: 10.1176/jnp.2008.20.4.466

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  34 in total

1.  Clinical markers of early disease in persons near onset of Huntington's disease.

Authors:  J S Paulsen; H Zhao; J C Stout; R R Brinkman; M Guttman; C A Ross; P Como; C Manning; M R Hayden; I Shoulson
Journal:  Neurology       Date:  2001-08-28       Impact factor: 9.910

2.  Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study.

Authors:  A Feigin; K L Leenders; J R Moeller; J Missimer; G Kuenig; P Spetsieris; A Antonini; D Eidelberg
Journal:  J Nucl Med       Date:  2001-11       Impact factor: 10.057

3.  Cognitive and motor functioning in gene carriers for Huntington's disease: a baseline study.

Authors:  Marie-Noëlle W Witjes-Ané; Maria Vegter-van der Vlis; Jeroen P P van Vugt; Jan B K Lanser; Jo Hermans; Aeilko H Zwinderman; Gert-Jan B van Ommen; Raymund A C Roos
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2003       Impact factor: 2.198

4.  Neuropsychological manifestations of the genetic mutation for Huntington's disease in presymptomatic individuals.

Authors:  Jason Brandt; Barnett Shpritz; Ann Marie Codori; Russell Margolis; Adam Rosenblatt
Journal:  J Int Neuropsychol Soc       Date:  2002-11       Impact factor: 2.892

5.  Memory and learning are not impaired in presymptomatic individuals with an increased risk of Huntington's disease.

Authors:  G M de Boo; A A Tibben; J A Hermans; A Jennekens-Schinkel; A Maat-Kievit; R A Roos
Journal:  J Clin Exp Neuropsychol       Date:  1999-12       Impact factor: 2.475

6.  Single photon emission computerized tomography (SPECT) in detecting neurodegeneration in Huntington's disease.

Authors:  N C Reynolds; R S Hellman; R S Tikofsky; R W Prost; L P Mark; B R Elejalde; R Lebel; K S Hamsher; S Swanson; E E Benezra
Journal:  Nucl Med Commun       Date:  2002-01       Impact factor: 1.690

7.  Psychomotor, executive, and memory function in preclinical Huntington's disease.

Authors:  J S Snowden; D Craufurd; J Thompson; D Neary
Journal:  J Clin Exp Neuropsychol       Date:  2002-04       Impact factor: 2.475

8.  Longitudinal study evaluating neuropsychological changes in so-called asymptomatic carriers of the Huntington's disease mutation after 1 year.

Authors:  J Lemiere; M Decruyenaere; G Evers-Kiebooms; E Vandenbussche; R Dom
Journal:  Acta Neurol Scand       Date:  2002-09       Impact factor: 3.209

9.  Attention, inhibition, and proximity to clinical onset in preclinical mutation carriers for Huntington's disease.

Authors:  Maree Farrow; Andrew Churchyard; Phyllis Chua; John L Bradshaw; Edmond Chiu; Nellie Georgiou-Karistianis
Journal:  J Clin Exp Neuropsychol       Date:  2007-04       Impact factor: 2.475

Review 10.  Future directions in research with presymptomatic individuals carrying the gene for Huntington's disease.

Authors:  Nellie Georgiou-Karistianis; Eleanor Smith; John L Bradshaw; Phyllis Chua; John Lloyd; Andrew Churchyard; Edmond Chiu
Journal:  Brain Res Bull       Date:  2003-01-30       Impact factor: 4.077

View more
  12 in total

1.  Brain metabolite alterations and cognitive dysfunction in early Huntington's disease.

Authors:  Paul G Unschuld; Richard A E Edden; Aaron Carass; Xinyang Liu; Megan Shanahan; Xin Wang; Kenichi Oishi; Jason Brandt; Susan S Bassett; Graham W Redgrave; Russell L Margolis; Peter C M van Zijl; Peter B Barker; Christopher A Ross
Journal:  Mov Disord       Date:  2012-05-30       Impact factor: 10.338

2.  Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease.

Authors:  Robert C Wolf; Georg Grön; Fabio Sambataro; Nenad Vasic; Nadine D Wolf; Philipp A Thomann; Carsten Saft; G Bernhard Landwehrmeyer; Michael Orth
Journal:  J Cereb Blood Flow Metab       Date:  2011-05-11       Impact factor: 6.200

3.  Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.

Authors:  Jane S Paulsen; Jeffrey D Long; Christopher A Ross; Deborah L Harrington; Cheryl J Erwin; Janet K Williams; Holly James Westervelt; Hans J Johnson; Elizabeth H Aylward; Ying Zhang; H Jeremy Bockholt; Roger A Barker
Journal:  Lancet Neurol       Date:  2014-11-03       Impact factor: 44.182

4.  Depressive symptoms in prodromal Huntington's Disease correlate with Stroop-interference related functional connectivity in the ventromedial prefrontal cortex.

Authors:  Paul G Unschuld; Suresh E Joel; James J Pekar; Sarah A Reading; Kenichi Oishi; Julie McEntee; Megan Shanahan; Arnold Bakker; Russell L Margolis; Susan S Bassett; Adam Rosenblatt; Susumu Mori; Peter C van Zijl; Christopher A Ross; Graham W Redgrave
Journal:  Psychiatry Res       Date:  2012-09-11       Impact factor: 3.222

5.  Brain activation and functional connectivity in premanifest Huntington's disease during states of intrinsic and phasic alertness.

Authors:  Robert Christian Wolf; Georg Grön; Fabio Sambataro; Nenad Vasic; Nadine Donata Wolf; Philipp Arthur Thomann; Carsten Saft; G Bernhard Landwehrmeyer; Michael Orth
Journal:  Hum Brain Mapp       Date:  2011-08-25       Impact factor: 5.038

Review 6.  Determinants of functional disability in Huntington's disease: role of cognitive and motor dysfunction.

Authors:  Christopher A Ross; Alex Pantelyat; Jane Kogan; Jason Brandt
Journal:  Mov Disord       Date:  2014-09-15       Impact factor: 10.338

7.  Cognitive decline in prodromal Huntington Disease: implications for clinical trials.

Authors:  Jane S Paulsen; Megan M Smith; Jeffrey D Long
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-08-02       Impact factor: 10.154

8.  The Allure of High-Risk Rewards in Huntington's disease.

Authors:  Nelleke C van Wouwe; Kristen E Kanoff; Daniel O Claassen; K Richard Ridderinkhof; Peter Hedera; Madaline B Harrison; Scott A Wylie
Journal:  J Int Neuropsychol Soc       Date:  2015-12-28       Impact factor: 2.892

9.  Seven-year clinical follow-up of premanifest carriers of Huntington's disease.

Authors:  Ellen Hart; Huub Middelkoop; Caroline K Jurgens; Marie-Noëlle W Witjes-Ané; Raymund A C Roos
Journal:  PLoS Curr       Date:  2011-11-30

Review 10.  Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine Modulation.

Authors:  Claudia Rangel-Barajas; George V Rebec
Journal:  J Huntingtons Dis       Date:  2016-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.